Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAW039 in Uncontrolled Severe Asthma
NCT02555683Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of fevipiprant in severe asthma, sponsored by Novartis. Started Dec 2015; status: completed.
02
Drugs
fevipiprant
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT02555683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555683.